Importantly, a regulatory axis between HEY1-NCOA2 and Runx2 was identified: CRISPR-mediated knockout of Runx2 delayed tumor onset in vivo but resulted in poorly differentiated tumors dominated by small round cells. This evidence concerns the gene RUNX2 and neoplasm.